8-K: Serina Therapeutics Appoints New Auditor Following Merger, WithumSmith+Brown Replaced

Serina Therapeutics has replaced its auditor, WithumSmith+Brown, with Frazier & Deeter following the completion of its merger with AgeX Therapeutics.

Summary

• Serina Therapeutics, formerly known as AgeX Therapeutics, completed a merger on March 26, 2024, with Serina Therapeutics becoming a wholly-owned subsidiary.
• Following the merger, the company changed its name to Serina Therapeutics, Inc.
• On April 29, 2024, the Audit Committee approved the engagement of Frazier & Deeter, LLC as the new independent registered public accounting firm for the fiscal year ending December 31, 2024.
• WithumSmith+Brown, PC, the previous auditor, was informed of their dismissal.
• Withum's reports for the fiscal years ended December 31, 2023 and 2022 did not contain adverse opinions, disclaimers, or qualifications, except for a going concern uncertainty.
• There were no disagreements between the company and Withum regarding accounting principles, financial statement disclosure, or auditing scope.
• The company did not consult with Frazier & Deeter on accounting principles or audit opinions prior to their appointment.
• Withum has confirmed that they agree with the statements made in the Form 8-K regarding their dismissal.

Sentiment

Score: 7

Explanation: The document indicates a standard post-merger process with a change of auditors. The lack of disagreements with the previous auditor is positive, but the going concern issue remains a concern. Overall, the sentiment is neutral to slightly positive.

Positives

• The transition to a new auditor appears to be smooth with no reported disagreements or issues.
• Withum's audit reports did not contain any adverse opinions or qualifications, except for the going concern uncertainty, which is not uncommon for companies in this stage.

Negatives

• The previous auditor's report included a statement about substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is a risk factor that was highlighted by the previous auditor.
• The transition to a new auditor could present unforeseen challenges, although none are apparent at this time.

Management Comments

• The Audit Committee of the Board of Directors approved the engagement of Frazier & Deeter as the company's independent registered public accounting firm.

Industry Context

Changes in auditors are not uncommon after a merger or acquisition, as the new entity often seeks to align its financial reporting with its own preferences and practices. This change is a standard part of the post-merger integration process.

Comparison to Industry Standards

• The change of auditors after a merger is a common practice, and the selection of Frazier & Deeter is not unusual for a company of this size and stage.
• The lack of disagreements with the previous auditor, WithumSmith+Brown, is a positive sign, indicating a smooth transition.
• The going concern qualification in the previous audit report is not uncommon for early-stage biotech companies, and it is important to monitor the company's progress in addressing this issue.

Stakeholder Impact

• Shareholders should be aware of the change in auditors and the going concern issue highlighted in the previous audit report.
• The change in auditors is unlikely to have a significant impact on employees, customers, or suppliers.

Key Dates

Keywords

auditor, merger, accounting, Frazier & Deeter, WithumSmith+Brown, Serina Therapeutics, AgeX Therapeutics, financial statements